Sandoz stock: Enzeevu launch adds a US commercial channel
Published on 11/17/2026 at 17:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSUS launch broadens commercial reach
- Sandoz launched Enzeevu in the United States alongside a multi-year private-label agreement for additional commercial reach.
- Committed private-label volumes are scheduled to begin in the second half of 2027, while the company targets more than 100 biosimilars by 2040.
Sandoz announced on Monday, November 16, 2026, the US launch of Enzeevu, an aflibercept biosimilar for retinal diseases, alongside a multi-year private-label agreement. The company said the arrangement will add a further commercial channel in the United States.
Enzeevu is approved in a pre-filled syringe for several retinal conditions, including wet age-related macular degeneration, macular edema following retinal vein occlusion, diabetic retinopathy and diabetic macular edema. Sandoz said the product is interchangeable with the reference medicine for all approved indications.
Private-label volumes begin in 2027
Under the agreement, Sandoz will manufacture Enzeevu for private-label commercialization beginning in mid-2027. The company said committed volumes will start in the second half of 2027, but it did not disclose financial terms or volume figures.
The arrangement extends Sandoz's US commercialization model beyond its own label and adds to its ophthalmology portfolio. The company linked the launch to its Bio100 ambition of building a portfolio of more than 100 biosimilars by 2040.
Stock moves since the earlier report
Sandoz stock traded at 88.93 euros on Lang & Schwarz at 17:45 CET on Tuesday, November 17, 2026, 2.16 percent below the 90.89-euro quote cited in the report published at 12:34 p.m. the same day. The move separates the latest trading level from the company's commercial announcement.
Sandoz Group AG
- Company: Sandoz Group AG
- ISIN: CH1243598427
- Home exchange: SIX Swiss Exchange
- Lang & Schwarz price: 88.93 euros on November 17, 2026, at 17:45:51 CET
Investors can follow broader European market developments in the Current market reports.
